
Fangzhou launches world's first once-weekly basal insulin/GLP-1 therapy in China to improve diabetes care.
Fangzhou Inc. has launched Kyinsu®, the world's first once-weekly basal insulin/GLP-1 receptor agonist combination therapy, on its AI-powered Internet hospital platform in China, the first global market for this treatment. This therapy reduces insuli...



